News
The FDA has granted regenerative medicine advanced therapy designation to BEAM-101, a one-time, gene-edited cell therapy for severe SCD.
I’ve shared reflections from three days after my last sickle cell pain crisis, and then again a month later. Now, four months on, I find myself in a completely different place physically, mentally, ...
In her final column, Sylvia Amuta reflects on all she's learned from her experience as a caregiver to her young cousin with ...
Women with SCD have nearly double the rate of acute pain late in pregnancy and right after than in the months following birth ...
Columnist Oluwatosin Adesoye shares the qualities she looks for in a romantic partner as someone living with sickle cell ...
People with sickle cell disease may have a higher risk of developing blood cancer, but a lower risk for certain types of ...
Children with SCD who have sleep issues, such as sustained low blood oxygen during sleep, require more healthcare resources, ...
Pociredir 12 mg dose has shown favorable safety and signs of efficacy in a Phase 1b trial of sickle cell disease (SCD).
A student at Kennesaw State is helping develop a low-cost, light-based device to screen for stroke in children with sickle cell disease.
The first patient with SCD has been dosed in a clinical trial of HBI-002, an experimental, low-dose liquid formulation of carbon monoxide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results